Zimmer Biomet (ZBH) details resignation of named executive Mark Bezjak

Rhea-AI Filing Summary

Zimmer Biomet Holdings, Inc. reported that Mark Bezjak, who was identified as a named executive officer in the company’s 2025 proxy statement, has informed the company he will resign his employment. His resignation, including all officer positions with Zimmer Biomet and its affiliates, will be effective January 16, 2026 so he can pursue another business opportunity.

The company previously disclosed that Mr. Bezjak ceased to be an executive officer of Zimmer Biomet as of July 1, 2025, so this filing formalizes his departure from remaining roles with the organization.

false 0001136869 0001136869 2026-01-08 2026-01-08 0001136869 us-gaap:CommonStockMember 2026-01-08 2026-01-08 0001136869 zbh:M2.425NotesDue2026Member 2026-01-08 2026-01-08 0001136869 zbh:M1.164NotesDue2027Member 2026-01-08 2026-01-08 0001136869 zbh:M3.518NotesDue2032Member 2026-01-08 2026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-16407		13-4151777
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
345 East Main Street
Warsaw, Indiana				46580
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (574) 373-3333

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		ZBH		New York Stock Exchange
2.425% Notes due 2026		ZBH 26		New York Stock Exchange
1.164% Notes due 2027		ZBH 27		New York Stock Exchange
3.518% Notes due 2032		ZBH 32		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;Compensatory Arrangements of Certain Officers.

On January 8, 2026, Mark Bezjak, a named executive officer in the 2025 proxy statement of Zimmer Biomet Holdings, Inc. (the “Company”), informed the Company that he will resign his employment, including all officer positions with the Company and its affiliates, effective as of January 16, 2026, to pursue another business opportunity. As previously reported, Mr. Bezjak ceased to be an executive officer of the Company on July 1, 2025.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT INDEX

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 12, 2026

ZIMMER BIOMET HOLDINGS, INC.
By:		/s/ Chad F. Phipps
Name:		Chad F. Phipps
Title:		Senior Vice President, General Counsel and Secretary

FAQ

What executive change did Zimmer Biomet (ZBH) disclose on January 8, 2026?

Zimmer Biomet disclosed that Mark Bezjak, a named executive officer in its 2025 proxy statement, informed the company he will resign his employment and all officer positions effective January 16, 2026.

Was Mark Bezjak still an executive officer of Zimmer Biomet (ZBH) at the time of this 8-K?

No. The company states that Mr. Bezjak ceased to be an executive officer on July 1, 2025, and this filing addresses his subsequent resignation from employment and officer roles.

Why is Mark Bezjak leaving Zimmer Biomet (ZBH)?

Zimmer Biomet reports that Mr. Bezjak is resigning to pursue another business opportunity.

When will Mark Bezjak’s resignation from Zimmer Biomet (ZBH) become effective?

His resignation from employment and all officer positions with Zimmer Biomet and its affiliates will be effective January 16, 2026.

How was Mark Bezjak previously described in Zimmer Biomet’s (ZBH) disclosures?

He was identified as a named executive officer in Zimmer Biomet’s 2025 proxy statement.

Does this 8-K from Zimmer Biomet (ZBH) include financial results or earnings data?

No. The disclosure focuses on Mr. Bezjak’s resignation and does not present financial or earnings data.